The effect of magnesium sulfate on hemodynamic and respiratory parameters of multiple trauma patients under mechanical ventilation

To evaluate the effect of magnesium sulfate on hemodynamic and respiratory parameters of multiple trauma patients under mechanical ventilation

Phase III single-blind (assessor-blind) randomized controlled trial with parallel groups on 104 patients, randomization performed using a randomization table generated by the Random Allocation software

This study will include 104 multiple trauma patients under mechanical ventilation in Shahid Mohammadi Hospital intensive care unit, Bandar Abbas. Patients will be randomized into two groups. Patients in the intervention group will receive 2 g magnesium sulfate 20% in daily serum within the first 24 hours and those in the control group will only receive daily serum. Blood pressure, heart rate, oxygen saturation, pulmonary compliance, and airway resistance will be assessed every 6 hours and arterial blood gas every 12 hours by an individual blinded to the patient grouping (assessor-blind). Mechanical ventilation will be under volume control mode with 6 L tidal volume, 10-14/min respiratory rate, 40-50% fraction of inspired oxygen, positive end-respiratory pressure of 5, and pressure support of 10. Also, all patients will receive 50-100 mcg/h fentanyl and 1-2 mg/h midazolam.

Inclusion criteria: multiple trauma, mechanical ventilation, admission to the intensive care unit within 24 hours of trauma, age 18-70 years Exclusion criteria: history of pulmonary disease such as asthma and chronic obstructive pulmonary disease, pulmonary contusion, pneumothorax, cardiovascular instability

Intervention group: 2 g magnesium sulfate 20% in daily serum within the first 24 hours Control group: Only daily serum within the first 24 hours

Blood pressure, oxygen saturation (SpO2), heart rate, pulmonary compliance, airway resistance, arterial blood gas

Patients will be randomized into two groups using simple randomization with individuals as the unit of randomization and a randomization table produced by the Random Allocation software. An individual uninvolved in the study will write A or B on a card and put it in an opaque envelope. Then the associated number in the randomization table will be written on the back of the envelope. One envelope will be allocated to each patient in order of entrance to the study. Allocation concealment will be done using opaque envelopes.

The individual responsible for the assessment of hemodynamic and respiratory parameters will be unaware of patient grouping, while given the nature of the intervention and that there is no placebo, the patient and those related to the patient will not be blinded. Therefore, the study will be single-blind with blinding the assessor.

There is no further information.